BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...Prolactin PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking University Xoma Corp. 5-alpha reductase GnRH/LHRH...
BioCentury | Nov 18, 2013
Clinical News

Duodart dutasteride/tamsulosin regulatory update

...assessments once new legislation is in the works. Duodart is a combination of dutasteride, a 5-alpha reductase...
BioCentury | Aug 19, 2013
Clinical News

Proscar finasteride: Clinical trial data

...NYSE:MRK), Whitehouse Station, N.J. Product: Proscar finasteride Business: Cancer Molecular target: 5-alpha reductase Description: Type II 5-alpha reductase...
BioCentury | Feb 6, 2012
Clinical News

Avodart dutasteride: Phase IV data

...NYSE:GSK), London, U.K. Product: Avodart dutasteride ( GI198745 ) Business: Cancer Molecular target: 5-alpha reductase Description: 5-alpha reductase...
BioCentury | Jun 10, 2011
Company News

FDA issues warning on BPH drugs

...FDA said it updated the labels for 5-alpha reductase inhibitors to include information about an increased risk...
...high-grade prostate cancer. Proscar and Avodart are approved to treat benign prostatic hyperplasia (BPH). Other 5-alpha reductase...
BioCentury | Jan 31, 2011
Clinical News

Avodart dutasteride regulatory update

...abstentions, that the benefit-risk profile of Avodart did not support approval for the indication. The 5-alpha reductase...
BioCentury | Jan 28, 2011
Company News

Complete response for GSK's Avodart

...abstentions, that the benefit-risk profile of Avodart did not support approval for the indication. The 5-alpha reductase...
BioCentury | Dec 2, 2010
Company News

ODAC rebuffs Proscar, Avodart for prostate cancer

...the Prostate Cancer Prevention Trial (PCPT) suggesting the drug reduces risk of the disease. The 5-alpha reductase...
BioCentury | Nov 1, 2010
Clinical News

Avodart dutasteride regulatory update

...to include reduction in the risk of prostate cancer in men at increased risk. The 5-alpha reductase...
...has not proposed to expand the label or disclosed future plans for the Type II 5-alpha reductase...
BioCentury | Nov 1, 2010
Clinical News

Proscar finasteride regulatory update

...to include reduction in the risk of prostate cancer in men at increased risk. The 5-alpha reductase...
...has not proposed to expand the label or disclosed future plans for the Type II 5-alpha reductase...
Items per page:
1 - 10 of 27